BTIG Research Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) had its price target decreased by analysts at BTIG Research from $39.00 to $37.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research‘s target price would indicate a potential upside of 251.38% from the stock’s current price.

BCAX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, October 2nd. Morgan Stanley reiterated an “overweight” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 20th. HSBC cut shares of Bicara Therapeutics to an “equal weight” rating in a research note on Tuesday, September 22nd. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a research note on Tuesday. Finally, Mizuho boosted their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Read Our Latest Report on BCAX

Bicara Therapeutics Stock Up 3.4%

BCAX opened at $10.53 on Tuesday. Bicara Therapeutics has a twelve month low of $7.87 and a twelve month high of $30.99. The company has a 50-day simple moving average of $17.37 and a 200 day simple moving average of $20.84. The stock has a market capitalization of $696.80 million, a price-to-earnings ratio of -3.03 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). Sell-side analysts anticipate that Bicara Therapeutics will post -3.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Bicara Therapeutics in the second quarter worth about $114,250,000. Jupiter Topco LLC acquired a new stake in shares of Bicara Therapeutics in the 2nd quarter valued at approximately $93,957,000. Janus Henderson Group PLC grew its holdings in shares of Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares during the last quarter. Siren L.L.C. grew its holdings in shares of Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after purchasing an additional 586,001 shares during the last quarter. Finally, Palo Alto Investors LP bought a new stake in shares of Bicara Therapeutics during the 2nd quarter valued at approximately $16,341,614.

Top Bicara Therapeutics Stories

Investors following BCAX have been watching these stories:

  • Positive Sentiment: Bicara’s Q3 2026 earnings-call coverage highlighted strong enrollment momentum, a potentially encouraging sign for progress in its clinical programs. Article: Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights
  • Positive Sentiment: Despite reducing their targets, HC Wainwright, Morgan Stanley, Stifel Nicolaus and BTIG kept Buy or Overweight ratings. Their revised targets range from $30 to $43, substantially above the cited $10.53 share price, signaling that analysts still see considerable potential upside.
  • Neutral Sentiment: A report listed short interest at zero shares as of Nov. 10. That figure indicates no reported short position in the data, but provides little evidence of short-covering demand.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.

Recommended Stories

Analyst Recommendations for Bicara Therapeutics (NASDAQ:BCAX)

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.